FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892004965> ?p ?o ?g. }

• W2892004965 abstract "e14042 Background: BPM 31510 is a ubidecarenone containing nanodispersion elicits anticancer effect by switching cancer cells energy generation from glycolysis to mitochondrial OXPHOS; i.e. reverses Warburg effect. This Phase 1 study is evaluating safety of 144-hour infusion of BPM 31510 as a single agent and in combination with 3 standard chemotherapy regimens. The molecular adaptive study design enabled longitudinal multi-omic molecular profiling to delineate personalized cause-and-effect networks relating patient biology to clinical outcomes using unbiased Bayesian statistics based bAIcis Artificial Intelligence (AI) technology Methods: Eligible pts (aged ≥ 18 y) were relapsed/refractory to standard therapy. The monotherapy arm received IV BPM31510 for 144-hour infusion in 28d cycles, and combination arms (gemcitabine, 5-FU or docetaxel) were primed with BPM 31510 for 3 wks followed by weekly dosing in a 6wk cycle. Doses were escalated in a 3+3 schema. Endpoints were safety, PK and multi-omics analysis. Clinical information was processed and integrated with multi-omic molecular data (metabolomics, lipidomics and proteomics), utilized bAIcis to learn relationships and extract actionable information from pt records, molecular features and corresponding clinical response. Results: As of 10 Dec 2016, 97 pts have been enrolled. Hematologically-related DLTs were reported at 171mg/kg in monotherapy and 137mg/kg in the BPM31510+gemcitabine arm (maximum administered dose). The bAIcis-generated set of predictors defining coagulation-related events in the clinical trial population include proteins, lipids, and metabolites, the levels of which can potentially predict undesirable events prior to and 24h after the 1 st treatment with BPM 31510. Conclusions: BPM31510 is well tolerated as a monotherapy and in combination with chemotherapeutic agents. Molecular signatures of susceptibility have been identified through use of multi-omic based AI analysis. Molecular signatures predictive of coagulation-related events will be assessed in Phase 2 and 3 trials to guide the development plan for BPM 31510 as anticancer agent. Clinical trial information: NCT01957735." @default.
• W2892004965 created "2018-09-27" @default.
• W2892004965 creator A5008685777 @default.
• W2892004965 creator A5026095888 @default.
• W2892004965 creator A5043675371 @default.
• W2892004965 creator A5046491246 @default.
• W2892004965 creator A5049813595 @default.
• W2892004965 creator A5054206531 @default.
• W2892004965 creator A5057656484 @default.
• W2892004965 creator A5058081424 @default.
• W2892004965 creator A5067425323 @default.
• W2892004965 creator A5074830972 @default.
• W2892004965 creator A5085591989 @default.
• W2892004965 creator A5090366304 @default.
• W2892004965 date "2017-05-20" @default.
• W2892004965 modified "2023-09-27" @default.
• W2892004965 title "Bayesian AI to delineate molecular signatures of patient susceptibility to potential hematologic events in a phase I study of BPM31510 (ubidecarenone) in solid tumors." @default.
• W2892004965 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e14042" @default.
• W2892004965 hasPublicationYear "2017" @default.
• W2892004965 type Work @default.
• W2892004965 sameAs 2892004965 @default.
• W2892004965 citedByCount "0" @default.
• W2892004965 crossrefType "journal-article" @default.
• W2892004965 hasAuthorship W2892004965A5008685777 @default.
• W2892004965 hasAuthorship W2892004965A5026095888 @default.
• W2892004965 hasAuthorship W2892004965A5043675371 @default.
• W2892004965 hasAuthorship W2892004965A5046491246 @default.
• W2892004965 hasAuthorship W2892004965A5049813595 @default.
• W2892004965 hasAuthorship W2892004965A5054206531 @default.
• W2892004965 hasAuthorship W2892004965A5057656484 @default.
• W2892004965 hasAuthorship W2892004965A5058081424 @default.
• W2892004965 hasAuthorship W2892004965A5067425323 @default.
• W2892004965 hasAuthorship W2892004965A5074830972 @default.
• W2892004965 hasAuthorship W2892004965A5085591989 @default.
• W2892004965 hasAuthorship W2892004965A5090366304 @default.
• W2892004965 hasConcept C107673813 @default.
• W2892004965 hasConcept C121608353 @default.
• W2892004965 hasConcept C126322002 @default.
• W2892004965 hasConcept C143998085 @default.
• W2892004965 hasConcept C154945302 @default.
• W2892004965 hasConcept C2908731994 @default.
• W2892004965 hasConcept C41008148 @default.
• W2892004965 hasConcept C70721500 @default.
• W2892004965 hasConcept C71924100 @default.
• W2892004965 hasConcept C86803240 @default.
• W2892004965 hasConceptScore W2892004965C107673813 @default.
• W2892004965 hasConceptScore W2892004965C121608353 @default.
• W2892004965 hasConceptScore W2892004965C126322002 @default.
• W2892004965 hasConceptScore W2892004965C143998085 @default.
• W2892004965 hasConceptScore W2892004965C154945302 @default.
• W2892004965 hasConceptScore W2892004965C2908731994 @default.
• W2892004965 hasConceptScore W2892004965C41008148 @default.
• W2892004965 hasConceptScore W2892004965C70721500 @default.
• W2892004965 hasConceptScore W2892004965C71924100 @default.
• W2892004965 hasConceptScore W2892004965C86803240 @default.
• W2892004965 hasLocation W28920049651 @default.
• W2892004965 hasOpenAccess W2892004965 @default.
• W2892004965 hasPrimaryLocation W28920049651 @default.
• W2892004965 hasRelatedWork W2079389605 @default.
• W2892004965 hasRelatedWork W3101012847 @default.
• W2892004965 hasRelatedWork W3181876365 @default.
• W2892004965 isParatext "false" @default.
• W2892004965 isRetracted "false" @default.
• W2892004965 magId "2892004965" @default.
• W2892004965 workType "article" @default.